More on BIOV
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $21.48 |
|
|||
| Open | $21.48 | ||||
| 52 Wk High | $21.42 | ||||
| 52 Wk Low | $21.42 | ||||
| Day High | $21.48 | ||||
| Day Low | $21.48 | ||||
| P/E | N/A | ||||
| EPS | $-0.90 | ||||
| Volume | 0 | ||||
- BioVersys begins Phase 3 trial for antibiotic targeting resistant bacteria
- BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
- BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
- Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
- BioVersys partners with Hackensack Meridian Health on NTM treatments
- BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
- BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
- BioVersys gets FDA clearance to start phase 3 trial for BV100
- BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
- BioVersys doses first patient in phase 2b tuberculosis trial
Entities mentioned with BIOV
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- S1 | View Related Stories »
- IPO | View Related Stories »
- Earnings | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
